#Unfolder lymphoma trial

The patients received 4 or 6 consecutive cycles of R-CHOP delivered once every 2 weeks, followed or not by RT at 40 Gy delivered 4 weeks after the last R-CHOP cycle. Patients were stratified according to the modified International Prognostic Index, including lactate dehydrogenase, Eastern Cooperative Oncology Group performance status, age, and disease stage.

#Unfolder lymphoma trial

We conducted a randomized trial in patients with nonbulky limited-stage DLBCL to evaluate the benefit of RT after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The benefit of radiotherapy (RT) after chemotherapy in limited-stage diffuse large B-cell lymphoma (DLBCL) remains controversial. 29 Hematology and Cell Therapy Department, CIC INSERM U1415, CHU de Poitiers, and CIC INSERM 1402, Université de Poitiers, Poitiers, France.28 Hematology Biology, Nantes University Hospital, Nantes, France and.27 Pathology Department, CHU Montpellier, Montpellier, France.

26 Hematology and Cell Therapy Department, CIC INSERM U1415, CHU de Tours, Université François Rabelais, Tours, France.25 INSERM UMR 1236, Rennes University, Etablissement Français du Sang and Laboratoire d'Hématologie, CHU de Rennes, Rennes, France.24 Imaging Nuclear Medicine Department and Radiopharmaceutical and Bioclinical Department, CHU de Grenoble, INSERM U1039, Grenoble University, Grenoble, France.23 Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.22 Health Network of Pays de Loire, Nantes, France.21 Hematology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.20 Hematology and Cell Therapy Department, CIC U1415, Department EA4666, CHU Amiens, Amiens, France.19 Hematology Department, Centre Hospitalier du Mans, Le Mans, France.18 Hematology Department, Rennes University Hospital, INSERM UMR 1236, Rennes, France.

17 Hematology Department, Centre Hospitalier Regional Universitaire Besançon, INSERM UMR 1098, Université de Franche-Comté, Besançon, France.

16 Hematology Department, Centre Hospitalier Départemental de Vendée, La Roche-Sur-Yon, France.

15 Hematology Department, Centre Hospitalier de Vannes, Vannes, France.

14 Oncology Department, Médicale-Pôle Santé République, Clermont-Ferrand, France.

13 Hematology Department, CHU de Nantes, University of Nantes, INSERM team 10 UMR 892, Institut de Recherche en Santé de l'Université de Nantes, CIC Hospital Hôtel Dieu, Nantes, France.

12 Hematology Department, CHU d'Angers, Angers, France.

11 Radiotherapy Department, Centre Eugène Marquis, Rennes, France.

10 Hematology Department, Clinique Victor Hugo, Le Mans, France.

9 Hematology Department, Centre Hospitalier de la Côte Basque, Bayonne, France.

8 Hematology Department, Cancer Institute Lucien Neuwirth, Saint-Priest-en-Jarez, France.

7 Onco Hematology Department, Hospital University Grenoble, INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes, Site Santé, La Tronche, Grenoble, France.

6 Hematology and Cell Therapy Department, University Hospital of Bordeaux, Bordeaux, France.

5 Hematology Department, CHU Montpellier, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 5235, Montpellier, France.

4 Hematology and Cell Therapy Department, Clinical Investigation Center (CIC) INSERM U1415, CHU de Tours, Université François Rabelais, Tours, France.

3 Bergonié Bordeaux Institute and Bordeaux University, Bordeaux, France.

2 Hematology Department, Centre Hospitalier Universitaire (CHU) d'Amiens, INSERM U1245, Amiens, France.

1 Hematology Department, Rennes University Hospital, INSERM Research Unit 1236, Rennes, France.